Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Fulcrum Therapeutics, Inc. (FULC) Investors of Class Action and to Actively ParticipatePRNewsWire • 05/02/23
FULCRUM THERAPEUTICS, INC. (NASDAQ: FULC) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Fulcrum Therapeutics, Inc. (NASDAQ: FULC)PRNewsWire • 05/02/23
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Fulcrum Therapeutics, Inc. (FULC) InvestorsBusiness Wire • 05/02/23
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in Fulcrum Therapeutics, Inc. with Losses of $100,000 to Contact the FirmBusiness Wire • 05/01/23
FULCRUM ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Fulcrum Therapeutics, Inc. and Encourages Investors to Contact the FirmBusiness Wire • 04/29/23
Shareholder Alert: Robbins LLP Informs Investors of Class Action Against Fulcrum Therapeutics, Inc. (FULC)Business Wire • 04/28/23
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fulcrum Therapeutics, Inc. - FULCPRNewsWire • 03/23/23
Fulcrum Therapeutics, Inc. (FULC) Reports Q4 Loss, Misses Revenue EstimatesZacks Investment Research • 03/09/23
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for the Fourth Quarter and Full Year 2022GlobeNewsWire • 03/09/23
Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast on Thursday, March 9, 2023, at 8:00 a.m. ETGlobeNewsWire • 03/06/23
FULCRUM ALERT: Bragar Eagel & Squire, P.C. is Investigating Fulcrum Therapeutics, Inc. on Behalf of Fulcrum Stockholders and Encourages Investors to Contact the FirmBusiness Wire • 03/04/23
INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Fulcrum Therapeutics, Inc. and Encourages Investors with Losses to Contact the FirmAccesswire • 03/03/23
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Fulcrum Therapeutics, Inc. (FULC) InvestigationBusiness Wire • 03/02/23
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Fulcrum Therapeutics, Inc. (FULC) on Behalf of InvestorsBusiness Wire • 03/02/23
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Fulcrum Therapeutics, Inc. and Encourages Investors with Losses to Contact the FirmBusiness Wire • 03/02/23
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Fulcrum Therapeutics, Inc. (FULC) on Behalf of InvestorsBusiness Wire • 03/02/23
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Fulcrum Therapeutics, Inc. and Encourages Investors with Losses to Contact the FirmBusiness Wire • 03/02/23
The Law Offices of Frank R. Cruz Announces Investigation of Fulcrum Therapeutics, Inc. (FULC) on Behalf of InvestorsBusiness Wire • 03/01/23
Fulcrum Therapeutics Announces Clinical Hold on FTX-6058 in Sickle Cell DiseaseGlobeNewsWire • 02/24/23
Fulcrum Therapeutics, Inc. (FULC) May Report Negative Earnings: Know the Trend Ahead of Q4 ReleaseZacks Investment Research • 02/23/23
Wall Street Analysts Think Fulcrum Therapeutics, Inc. (FULC) Could Surge 71.81%: Read This Before Placing a BetZacks Investment Research • 02/16/23